CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
377.35MUSDvs all stocks (USD)
Revenue (TTM)
301.79MUSDvs all stocks (USD)
Profit Margin
-14.39%Beta
1.32xvs all stocks
52-Week Change
-37.85%vs all stocks
Market Capitalization
377.35MUSDvs all stocks (USD)
Enterprise Value
507.61MUSDvs all stocks (USD)
Forward P/E
23.46xPrice to Sales (TTM)
1.23xEnterprise to Revenue
1.68xEnterprise to EBITDA
-21.93xGross Margin
66.86%Profit Margin
-14.39%Operating Margin
-9.38%Return on Assets (TTM)
-9.06%Revenue (TTM)
301.79MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.65USDUpdated Jul 18, 2026Quarterly Revenue Growth
6.70%Gross Profit (TTM)
199.35MUSDvs all stocks (USD)
EBITDA (TTM)
-23.15MUSDvs all stocks (USD)
Net Income (TTM)
-43.42MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.74%Operating Cash Flow (TTM)
-36.59MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-23.23MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
297.18MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
100.07MUSDFY2025 · Dec 31, 2025Gross Profit
197.11MUSDFY2025 · Dec 31, 2025Operating Income
-37.60MUSDvs all stocks (USD)
Pre-tax Income
-50.96MUSDFY2025 · Dec 31, 2025Income Tax Expense
677.00KUSDFY2025 · Dec 31, 2025Net Income
-51.64MUSDFY2025 · Dec 31, 2025EBIT
-31.27MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-21.08MUSDFY2025 · Dec 31, 2025Research & Development
9.58MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
220.79MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.93MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
19.69MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.8000USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.8000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
64.47MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
64.47MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-51.64MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-42.06MUSDFY2025 · Dec 31, 2025Free Cash Flow
-45.50MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
53.83MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.22MUSDFY2025 · Dec 31, 2025Interest Paid
14.79MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-51.64MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.74MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
21.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
20.70MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-4.13MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.51MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
10.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.35MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.44MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.44MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
25.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-15.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-8.81MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
16.17MUSDFY2025 · Dec 31, 2025Shares Outstanding
65.84MSharesUpdated Jul 18, 2026Float Shares
50.04MSharesUpdated Jul 18, 2026Shares Short
6.02MSharesUpdated Jul 18, 2026Short Ratio
7.66daysvs all stocks
Short % of Shares Outstanding
9.25%vs all stocks
% Held by Insiders
14.68%vs all stocks
% Held by Institutions
70.35%vs all stocks
Total Cash (MRQ)
49.79MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7560USDUpdated Jul 18, 2026Total Debt (MRQ)
164.90MUSDvs all stocks (USD)
Current Ratio (MRQ)
2.04xBook Value per Share (MRQ)
-0.4370USDUpdated Jul 18, 2026Total Assets
225.87MUSDvs all stocks (USD)
Total Current Assets
142.92MUSDFY2025 · Dec 31, 2025Total Liabilities
248.97MUSDFY2025 · Dec 31, 2025Total Non-current Assets
82.95MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
173.67MUSDFY2025 · Dec 31, 2025Total Current Liabilities
75.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
53.83MUSDFY2025 · Dec 31, 2025Accounts Receivable
54.70MUSDFY2025 · Dec 31, 2025Inventory
26.96MUSDFY2025 · Dec 31, 2025Accounts Payable
23.36MUSDFY2025 · Dec 31, 2025Short-term Debt
2.53MUSDFY2025 · Dec 31, 2025Deferred Revenue
11.55MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.30MUSDFY2025 · Dec 31, 2025Long-term Debt
152.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-661.04MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-23.11MUSDvs all stocks (USD)
52-Week Low
3.86USDUpdated Jul 18, 202652-Week High
10.20USDUpdated Jul 18, 202652-Week Change
-37.85%vs all stocks
Beta
1.32xvs all stocks
50-Day MA
6.57USDUpdated Jul 18, 2026200-Day MA
5.90USDUpdated Jul 18, 2026Avg 10-Day Volume
798.10KSharesUpdated Jul 18, 2026Avg 30-Day Volume
788.10KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.6600USDUpdated Jul 18, 2026Other Income / Expense
4.40MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.67Profit Margin: -0.14
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
PureTech Health plc
Tier 1ProductionApproval-Gated PipelineRiskInterface
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
OmniAb, Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Shanghai Model Organisms Center Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Ginkgo Bioworks Holdings Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Tilray Brands, Inc.
Tier 1ProductionApproval-Gated PipelineFlowAttention
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
XOMA Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Vireo Growth Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface